Nutriband Inc. Warrant - NTRBW STOCK NEWS

Q: What is Nutriband Inc.'s goal in the pharmaceutical industry?

Nutriband Inc. aims to utilize its proprietary AVERSA&#8482; abuse-deterrent technology to enhance the safety and effectiveness of transdermal drugs while maintaining accessibility for patients in need.

Welcome to our dedicated page for Nutriband Warrant news (Ticker: NTRBW), a resource for investors and traders seeking the latest updates and insights on Nutriband Warrant stock.

Nutriband Inc. is a health and pharmaceutical company based in Oviedo, Florida, primarily focusing on transdermal and topical technologies for product development. Their lead product, AVERSA technology, works to prevent drug abuse and diversion, especially opioids. Most revenue is generated from consumer transdermal and coated products. Nutriband is progressing towards a 505(b)(2) NDA submission to the FDA for marketing approval of AVERSA™ Fentanyl in Q1 2025.

The recent private placement of $8.4 million will fund the commercial development of AVERSA Fentanyl for NDA filing. Nutriband is working on the commercial scale-up and pivotal clinical study for FDA approval. AVERSA technology aims to revolutionize opioid patches with abuse-deterrent properties, making them safer and more effective.

By utilizing their proprietary AVERSA™ abuse-deterrent technology, Nutriband is dedicated to preventing drug abuse and misuse while ensuring accessibility to those in need. With a focused approach on innovation and safety, Nutriband is positioned to make a significant impact in the pharmaceutical industry.

01/29/2024 07:00 AM

News

Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1st

Rhea-AI Summary

Nutriband Inc. (NTRB) is set to present at The Microcap Conference in Atlantic City from January 30th to February 1st. CEO Gareth Sheridan will deliver two presentations and address questions. The company aims to showcase its potential to investors and traders.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

2.83%

Tags

01/26/2024 07:00 AM

News

Nutriband CEO Publishes Letter to Shareholders

Rhea-AI Summary

Nutriband Inc. CEO Gareth Sheridan published a letter to shareholders outlining the company's achievements in 2023 and targets for 2024. The company made significant strides in developing transdermal pharmaceutical products, securing new IP, and signing a commercial development and clinical supply agreement with Kindeva Drug Delivery for AVERSA Fentanyl, estimated to potentially reach peak annual sales of $80M - $200M. The company also reported strong revenue growth in 2023 and aims to expand its revenue opportunities through marketing initiatives and new product launches in 2024.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.03%

Tags

01/05/2024 09:15 AM

News

Nutriband Signs Commercial Development and Clinical Supply Agreement With Kindeva Drug Delivery for Aversa(TM) Fentanyl, an Abuse Deterrent Fentanyl Patch

Rhea-AI Summary

Nutriband Inc. (NTRB) announced a commercial development and clinical supply agreement for their lead product, Aversa™ Fentanyl, with Kindeva Drug Delivery. The agreement aims to support a New Drug Application (NDA) with the FDA, replacing a previous feasibility agreement. Aversa™ Fentanyl is estimated to have the potential to reach peak annual US sales of $80M - $200M.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

16.14%

Tags

11/28/2023 07:00 AM

News

Nutriband Inc. Expands its AI Kinesiology Tape Portfolio with the Launch of AI Tape Heating and Cooling

Rhea-AI Summary

Nutriband Inc. (NTRB) launches Heating and Cooling Kinesiology Tape under AI Tape brand, offering pain-relieving ingredients for temporary relief of minor aches and pains. The product is the second launch this year, manufactured in the USA at Nutriband's facility in North Carolina, and available for purchase on Amazon and Activeintell.com.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-7.72%

Tags

11/08/2023 07:00 AM

News

Nutriband Inc. Signs Supplier Agreement With KT Tape, the World Leader in Kinesiology Tape

Rhea-AI Summary

Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announces supplier agreement with KT Tape, a market leading kinesiology tape company, for a new line of specialized KT tape. The agreement showcases Nutriband's manufacturing capabilities and positions the company to develop innovative new product technologies with one of the world's largest brands, KT Tape.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.45%

Tags

10/11/2023 08:00 AM

News

Nutriband’s Aversa(TM) Buprenoprhine May Reach Peak Annual Sales 0f $70-130 Million Based on Market Assessment by Leading Healthcare Consulting Firm

Rhea-AI Summary

Nutriband completes market assessment and commercialization strategy for Aversa Buprenorphine transdermal system.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

2.56%

Tags

09/20/2023 07:30 AM

News

Nutriband Announces Issuance of U.S. Patent for Transdermal Abuse Deterrent Technology

Rhea-AI Summary

Nutriband Inc. expands patent portfolio for AVERSA™ transdermal abuse deterrent technology, potentially reaching peak annual U.S. sales of $80M - $200M.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-4.92%

Tags

09/12/2023 07:00 AM

News

Nutriband Inc. Receives Five Nominations in the Pharma Industry Awards 2023

Rhea-AI Summary

Nutriband Inc. has been shortlisted for 5 awards at the Pharma Industry Awards 2023, recognizing their innovative development of AVERSA abuse-deterrent transdermal technology.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-10.18%

Tags

09/11/2023 07:00 AM

News

Nutriband Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary

Nutriband Inc. reports a 48% increase in Q2 2023 revenues compared to Q2 2022, with quarterly revenue of $655,928. Stockholders' equity is $6.9 million as of July 31, 2023. The launch of AI Tape brand and partnership with Donovan McNabb as brand ambassador are seen as positive milestones for the company.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

8.78%

Tags

08/30/2023 08:00 AM

News

Nutriband Inc. Announces Donovan McNabb as AI Tape Brand Ambassador

Rhea-AI Summary

Nutriband engages Donovan McNabb as brand ambassador for AI Tape, targeting the $236M Elastic Therapeutic Tape market. McNabb's reputation as a pro athlete will deliver exposure and value to the brand. Global market expected to grow to $733.21M by 2033 with a CAGR of 12.0%.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

FAQ

What is the current stock price of Nutriband Warrant (NTRBW)?

The current stock price of Nutriband Warrant (NTRBW) is $1.3 as of October 31, 2024.

What is Nutriband Inc.'s primary focus?

Nutriband Inc. is primarily focused on transdermal and topical technologies for product development, with a specific emphasis on preventing drug abuse and diversion.

What is AVERSA technology?

AVERSA technology is Nutriband Inc.'s lead product designed to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, particularly opioids.

What is the recent achievement of Nutriband Inc.?

Nutriband Inc. closed an $8.4 million private placement to fund the commercial development of AVERSA Fentanyl, aimed at advancing towards FDA approval and revolutionizing opioid patches with abuse-deterrent properties.

What is Nutriband Inc.'s goal in the pharmaceutical industry?

Nutriband Inc. aims to utilize its proprietary AVERSA™ abuse-deterrent technology to enhance the safety and effectiveness of transdermal drugs while maintaining accessibility for patients in need.

How is Nutriband Inc. striving for innovation?

Through a focused approach on innovation and safety, Nutriband is dedicated to developing solutions that prevent drug abuse and misuse, contributing to a safer pharmaceutical industry.